Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 6Non-Muscle Invasive Bladder Neoplasms 5Glioma 4Carcinoma, Transitional Cell 3Wilms Tumor 2Urothelial Cancer 2Rhabdoid Tumor 2Prostatic Neoplasms 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Multiple Myeloma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Ependymoma 2Central Nervous System Neoplasms 2Xanthogranuloma, Juvenile 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rectal Neoplasms 1Pancreatic Neoplasms 1

Interventions

Nivolumab 6Specimen Handling 5Magnetic Resonance Spectroscopy 4Gemcitabine 4Cisplatin 4pembrolizumab 3cabozantinib 3avelumab 3Ipilimumab 3Carboplatin 3CTLA-4 Antigen 3enfortumab vedotin 2Immunoglobulin G 2Disulfides 2Biopsy 2tremelimumab 1trastuzumab deruxtecan 1tocilizumab 1tamibarotene 1relatlimab 1eribulin 1erdafitinib 1durvalumab 1atezolizumab 1Propranolol 1Platinum 1Leucovorin 1Lenalidomide 1Fluorouracil 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urethral Neoplasms × erdafitinib × 1 year × Clear all
NCT04963153 2026-05-13

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

National Cancer Institute (NCI)

Phase 1 Active not recruiting
24 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡